BACKGROUND: The purpose of this study was to define contemporary management recommendations regarding who would benefit from surgical excision of intraductal papilloma (IDP). METHODS: A prospective database from a single institution identified patients with IDP on percutaneous biopsy from February 2015 to September 2020. Categorical patient demographic, biopsy, and pathologic variables were analyzed using Fisher's exact test and continuous demographic and imaging variables using the Mann-Whitney U test. RESULTS: IDP was present in 416 biopsies, at a median age of 56 years. The median size was 0.9 cm, and the majority had greater than 50% of the target excised by biopsy. Surgical excision was performed for 124 of 416 biopsies (29.8%). Upgrade to malignancy was identified in 14 (11.3%): 8 to ductal carcinoma in situ (DCIS) and 6 to invasive cancer. Upgrade was significantly associated with concurrent ipsilateral breast cancer (p = 0.027), larger imaging size (p = 0.045), <50% excised with biopsy (p = 0.02), and atypia involving IDP (p = 0.045). Age, clinical presentation, and concurrent contralateral cancer were not significantly associated with upgrade. Lowest upgrade risk (0%) was in pure IDP ≤1 cm with >50% removed by biopsy. Of 401 biopsies that either did not upgrade or undergo excision, 7 (1.7%) developed subsequent breast cancer over a median follow-up of 23.5 months (interquartile range [IQR] 11,41), none at IDP site. CONCLUSIONS: After multidisciplinary review, the management of IDP can be stratified into low- and high-risk for upgrade groups using key criteria. Low-risk group may omit surgical excision, because those patients have 0% risk of upgrade over the limited short-term follow-up.
BACKGROUND: The purpose of this study was to define contemporary management recommendations regarding who would benefit from surgical excision of intraductal papilloma (IDP). METHODS: A prospective database from a single institution identified patients with IDP on percutaneous biopsy from February 2015 to September 2020. Categorical patient demographic, biopsy, and pathologic variables were analyzed using Fisher's exact test and continuous demographic and imaging variables using the Mann-Whitney U test. RESULTS: IDP was present in 416 biopsies, at a median age of 56 years. The median size was 0.9 cm, and the majority had greater than 50% of the target excised by biopsy. Surgical excision was performed for 124 of 416 biopsies (29.8%). Upgrade to malignancy was identified in 14 (11.3%): 8 to ductal carcinoma in situ (DCIS) and 6 to invasive cancer. Upgrade was significantly associated with concurrent ipsilateral breast cancer (p = 0.027), larger imaging size (p = 0.045), <50% excised with biopsy (p = 0.02), and atypia involving IDP (p = 0.045). Age, clinical presentation, and concurrent contralateral cancer were not significantly associated with upgrade. Lowest upgrade risk (0%) was in pure IDP ≤1 cm with >50% removed by biopsy. Of 401 biopsies that either did not upgrade or undergo excision, 7 (1.7%) developed subsequent breast cancer over a median follow-up of 23.5 months (interquartile range [IQR] 11,41), none at IDP site. CONCLUSIONS: After multidisciplinary review, the management of IDP can be stratified into low- and high-risk for upgrade groups using key criteria. Low-risk group may omit surgical excision, because those patients have 0% risk of upgrade over the limited short-term follow-up.
Authors: Martha Elizabeth Glenn; Alyssa D Throckmorton; John B Thomison; Robert S Bienkowski Journal: Ann Surg Oncol Date: 2014-10-15 Impact factor: 5.344
Authors: Lianqun Qiu; Daniel D Mais; Marlo Nicolas; Jennifer Nanyes; Kenneth Kist; Alia Nazarullah Journal: Int J Surg Pathol Date: 2019-06-12 Impact factor: 1.271
Authors: Sayee Kiran; Young Ju Jeong; Maria E Nelson; Alexander Ring; Meade B Johnson; Pulin A Sheth; Yanling Ma; Stephen F Sener; Julie E Lang Journal: J Surg Res Date: 2018-06-29 Impact factor: 2.192
Authors: Monica Rizzo; Mary Jo Lund; Gabriela Oprea; Matthew Schniederjan; William C Wood; Marina Mosunjac Journal: Ann Surg Oncol Date: 2008-01-18 Impact factor: 5.344
Authors: Song-Hee Han; Milim Kim; Yul Ri Chung; Bo La Yun; Mijung Jang; Sun Mi Kim; Eunyoung Kang; Eun-Kyu Kim; So Yeon Park Journal: J Breast Cancer Date: 2018-03-23 Impact factor: 3.588
Authors: Faina Nakhlis; Gabrielle M Baker; Melissa Pilewskie; Rebecca Gelman; Katherina Z Calvillo; Kandice Ludwig; Priscilla F McAuliffe; Shawna Willey; Laura H Rosenberger; Catherine Parker; Kristalyn Gallagher; Lisa Jacobs; Sheldon Feldman; Paulina Lange; Stephen D DeSantis; Stuart J Schnitt; Tari A King Journal: Ann Surg Oncol Date: 2020-10-12 Impact factor: 5.344